Alliance for Pandemic Preparedness

July 20, 2020

Articles Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older : A Randomised , Double-Blind , Placebo- Controlled , Phase 2 Trial

Category:

Topic:

  • Zhu et al. conducted a randomized, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine to determine the immunogenicity and incidence of adverse reactions.  
  • Both  doses  of  the  vaccine  induced  significant  neutralizing  antibody  responses  to  live  SARS-CoV-2. Evidence of antigen-specific T-cell responses were observed in 88-90% of vaccine recipients. 
  • Within 14 days, 72% of participants in one vaccine dose group and 74% of participants in another dose group reported at least one adverse reaction, both of which were significantly higher than the 37% of participants in the placebo group. Common reactions included fatigue, fever, headache, and pain at the injection site. However, no serious adverse events were documented within 28 days after injection.  

Zhu et al. (July 20, 2020). Articles Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older : A Randomised , Double-Blind , Placebo- Controlled , Phase 2 Trial. The Lancet. https://doi.org/10.1016/S0140-6736(20)31605-6